787), respectively; those for CT were 0.876 (95% CI, 0.829-0.923) and 0.608 (95% CI, 0.527-0.690), respectively. Tumor border index on MRI, but not CT, had superior diagnostic performance (P < .05); MRI- and CT-based rad-scores showed similar performance (P >.05). MRI is superior to CT for tumor margin examination; however, the radiomics features of both modalities showed no difference. MRI is superior to CT for tumor margin examination; however, the radiomics features of both modalities showed no difference. The objective of this study was to assess the duration of effect of a single dose of Biotène Moisturizing Spray on xerostomia compared to water spray. This double-blind randomized controlled crossover trial compared the duration of effect of 2 agents on relieving xerostomia in adult patients recruited through convenience sampling. Following a xerostomia questionnaire, qualifying patients with an unstimulated whole saliva flow rate of ≤0.20 mL/min rated their baseline level of discomfort from oral dryness and received a single dose (3 sprays) of Biotène Moisturizing Spray or water (active control). Patients indicated their level of oral discomfort every 15 min and the precise time when relief ceased. After a minimum 48-h washout, patients repeated the exercise with the alternative product. The baseline severity of discomfort from oral dryness among qualifying patients was significantly related to their level of hyposalivation (P=.001). The mean duration of effect of Biotène Moisturizing Spray was 27 ± 25 min, which was not significantly different from that for water (26 ± 25 min; P=.88; n=25). Biotène Moisturizing Spray and water spray had variable durations of effect averaging approximately 30 min. The results of this pilot study provide guidance regarding anticipated usage and dispensing needs for patients with objective xerostomia. ClinicalTrials.gov NCT03663231. Biotène Moisturizing Spray and water spray had variable durations of effect averaging approximately 30 min. The results of this pilot study provide guidance regarding anticipated usage and dispensing needs for patients with objective xerostomia. ClinicalTrials.gov NCT03663231. There is a disproportionately higher trauma morbidity between American Indian/Alaska Native (AI/AN) and non-AI/AN children. To characterize and compare trauma in AI/AN and non-AI/AN children presenting to a Regional Pediatric Level II Trauma Center (Adult Level I Trauma Center). A retrospective observational study of all children <20 years presenting from 2012-2018. Descriptive data were analyzed along with T-tests to determine if demographic and clinical characteristics were different for AI/AN and non-AI/AN children. AI/AN children are more likely to be referred from outside hospitals [OR 5.61, 95% CI 3.79, 8.29], to have penetrating injuries [OR 3.87, 95% CI 1.88, 7.99] and have higher likelihood of both minor [OR 1.48, 95% Cl 1.06, 2.07] and major [OR 1.99, 95% Cl 1.37, 2.87] trauma activation on arrival. More AI/AN children suffer violent injuries [OR 3.12, 95% CI 1.90, 5.01], utilized Intensive Care Unit (ICU) [OR 1.54 95% CI 1.10, 2.14], had prolonged length of stay (LOS) [OR 1.52, 95% Cl 1.28, 1.80], and were less likely discharged home [OR 0.65, 95% Cl 0.44, 0.96]. AI/AN pediatric trauma patients suffer higher morbidity compared to non-AI/AN pediatric trauma patients. This study provides data which supports the need for future interventions to decrease the burden of injury noted among AI/AN children. Treatment STUDY TYPE AND LEVEL OF EVIDENCE Retrospective comparative study; Level III. Treatment STUDY TYPE AND LEVEL OF EVIDENCE Retrospective comparative study; Level III.Osteopenia occurs in a subset of phenylalanine hydroxylase (PAH) deficient phenylketonuria (PKU) patients. While osteopenia is not fully penetrant in patients, the Pahenu2 classical PKU mouse is universally osteopenic, making it an ideal model of the phenotype. Pahenu2 Phe management, with a Phe-fee amino acid defined diet, does not improve bone density as histomorphometry metrics remain indistinguishable from untreated animals. Previously, we demonstrated Pahenu2 mesenchymal stem cells (MSCs) display impaired osteoblast differentiation. Oxidative stress is recognized in PKU patients and PKU animal models. https://www.selleckchem.com/products/Dihydroartemisinin(DHA).html Pahenu2 MSCs experience oxidative stress determined by intracellular superoxide over-representation. The deleterious impact of oxidative stress on mitochondria is recognized. Oximetry applied to Pahenu2 MSCs identified mitochondrial stress by increased basal respiration with concurrently reduced maximal respiration and respiratory reserve. Proton leak secondary to mitochondrial complex 1 dysfunction is a recognized superoxide source. Respirometry applied to Pahenu2 MSCs, in the course of osteoblast differentiation, identified a partial complex 1 deficit. Pahenu2 MSCs treated with the antioxidant resveratrol demonstrated increased mitochondrial mass by MitoTracker green labeling. In hyperphenylalaninemic conditions, resveratrol increased in situ alkaline phosphatase activity suggesting partial recovery of Pahenu2 MSCs osteoblast differentiation. Up-regulation of oxidative energy production is required for osteoblasts differentiation. Our data suggests impaired Pahenu2 MSC developmental competence involves an energy deficit. We posit energy support and oxidative stress reduction will enable Pahenu2 MSC differentiation in the osteoblast lineage to subsequently increase bone density. Tribulus terrestris L. (T. terrestris) positive performance on the male sexual system has been confirmed, but little is known about its effects on the female reproductive system. This review discussed in detail the beneficial impact of T. terrestris and its secondary metabolites on the female reproductive system. In this review, the scientific Databases of Science direct, Pubmed, Web of Science, Google, Google Scholar, Researchgate, EMBASE, Scientific Information (SID), and Elsevier were searched profoundly. Studies about the pharmacological activities of T. terrestris on the female reproductive system in each aspect of investigations human, in vivo, and in vitro studies, in the period from 1998 to 2020 were admitted. Our study was not limited by the language of publications. 23 articles about the effects of T. terrestris on the female reproductive system were found. These studies approved the T. terrestris efficacy on improvements in histological features of the ovary and uterus of polycystic ovary syndrome patients as well as the well-working of normal ovaries, enhancements in the sexual desire of postmenopausal syndrome, improve ovarian and breast cancers.